The Effects of Two Polymorphisms on p21cip1 Function and Their Association with Alzheimer’s Disease in a Population of European Descent
Open accessThe DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Abstract
With the exception of ApoE4, genome-wide association studies have failed to identify strong genetic risk factors for late-onset Alzheimer's disease, despite strong evidence of heritability, suggesting that many low penetrance genes may be involved. Additionally, the nature of the identified genetic risk factors and their relation to disease pathology is also largely obscure. Previous studies have found that a cancer-associated variant of the cell cycle inhibitor gene p21cip1 is associated with increased risk of Alzheimer's disease. The aim of this study was to confirm this association and to elucidate the effects of the variant on protein function and Alzheimer-type pathology. We examined the association of the p21cip1 variant with Alzheimer's disease and Parkinson's disease with dementia. The genotyping studies were performed on 719 participants of the Oxford Project to Investigate Memory and Ageing, 225 participants of a Parkinson's disease DNA bank, and 477 participants of the Human Random Control collection available from the European Collection of Cell Cultures. The post mortem studies were carried out on 190 participants. In the in-vitro study, human embryonic kidney cells were transfected with either the common or rare p21cip1 variant; and cytometry was used to assess cell cycle kinetics, p21cip1 protein expression and sub-cellular localisation. The variant was associated with an increased risk of Alzheimer's disease, and Parkinson's disease with dementia, relative to age matched controls. Furthermore, the variant was associated with an earlier age of onset of Alzheimer's disease, and a more severe phenotype, with a primary influence on the accumulation of tangle pathology. In the in-vitro study, we found that the SNPs reduced the cell cycle inhibitory and anti-apoptotic activity of p21cip1. The results suggest that the cancer-associated variant of p21cip1 may contribute to the loss of cell cycle control in neurons that may lead to Alzheimer-type neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“increased oxidative stress, which is already present in the very early stage of the disease and precedes the major pathologic hallmarks, such as senile plaques and neurofibrillary tangles [132,193].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [193]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 9×
“Pre-clinical: Entorhinal stage Alzheimer’s disease (Braak I and II); Mild AD: Limbic stage Alzheimer’s disease (Braak III and IV); Advanced AD: Neocortical stage Alzheimer’s disease (Braak V and VI).”
MethodInfluentialHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 1×
“The diagnosis of PD was made using the UK Parkinson’s Disease Society Brain Bank criteria [42].”
MethodMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · cited 1×
“The information available included the pathological diagnosis (CERAD protocol) [44] and the severity of AD as defined by Braak [45].”
MethodHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationBallard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Self-citationNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 1×
“Whilst the heritability of AD is up to 80% [2], so far, only one genetic risk factor, the E4 variant of the Apolipoprotein E gene (ApoE), is consistently shown to be associated with an increased risk and reduced age of onset.”
Background
Cited by
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“However, the evidence remains inconclusive, as a number of studies have reported increased levels in the brains of AD patients compared to controls [192,193], while others have found no significant differences [194].”
BackgroundCellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
“The other abnormal protein found in AD brains is hyperphosphorylated tau in the form of NFTs, which have been reported to induce senescence (Mendelsohn and Larrick, 2018).”
BackgroundInfluentialAyeb‐Karlsson, S., Kniveton, D., Cannon, T., van der Geest, K., Ahmed, I., Derrington, E. M., Florano, E., & Opondo, D. O. (2019) · Disasters · doi:10.1111/disa.12404 · Cited by 76
Senescence: A DNA damage response and its role in aging and Neurodegenerative Diseases
Shreeya, T., Ansari, M. S., Kumar, P., Saifi, M., Shati, A. A., Alfaifi, M. Y., & Elbehairi, S. E. I. (2024) · Frontiers in Aging · doi:10.3389/fragi.2023.1292053 · Cited by 84
DNA double-strand breaks: a potential therapeutic target for neurodegenerative diseases
Thadathil, N., Hori, R. T., Xiao, J., & Khan, M. M. (2019) · Chromosome Research · doi:10.1007/s10577-019-09617-x · Cited by 55
Ruíz-Agudelo, C. A., & Cortés-Gómez, A. M. (2021) · Environmental Challenges · doi:10.1016/j.envc.2021.100088 · Cited by 51
Parental reports on digital devices use in infancy and early childhood
Sivrikova, N. V., Ptashko, T., Perebeynos, A. E., Chernikova, E. G., Gilyazeva, N. V., & Vasilyeva, V. S. (2020) · Education and Information Technologies · doi:10.1007/s10639-020-10145-z · Cited by 57
DNA damage and neurodegenerative phenotypes in aged Ciz1 null mice
Khan, M. M., Xiao, J., Patel, D., & LeDoux, M. S. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.10.014 · Cited by 43
“…association studies have consistently identified variants in cell-cycle genes as susceptibility factors for mild cognitive impairment and dementia (Saykin et al., 2015) and two polymorphisms in CDKN1A are associated with increased risk and earlier age-of-onset of AD (Yates et al., 2015).”
BackgroundLourenço, A. P., Guidugli-Lazzarini, K. R., de Freitas, N. H. A., Message, D., Bitondi, M. M. G., Simões, Z. L. P., & Teixeira, É. W. (2021) · Journal of Insect Physiology · doi:10.1016/j.jinsphys.2021.104237 · Cited by 30
Connecting the dots: Neuronal senescence, stress granules, and neurodegeneration
Ma, Y., & Farny, N. G. (2023) · Gene · doi:10.1016/j.gene.2023.147437 · Cited by 33
Lei, K., Li, W., Huang, C., Li, Y., Alfason, L., Zhao, H., Miyagishi, M., Wu, S., & Kasim, V. (2019) · Cancer Science · doi:10.1111/cas.14233 · Cited by 30
Rao, C. V., Farooqui, M., Madhavaram, A., Zhang, Y., Asch, A. S., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13221 · Cited by 30
“NADH:Ubiquinone Oxidoreductase Core Subunit V1 (NDUFV1) was among the critical hippocampal genes and pathways that might be involved in the pathogenesis of human AD, identified via bioinformatics (Zhang et al., 2015).”
BackgroundAlzugaray, M. E., Bruno, M. C., Sambucaro, M. J. V., & Ronderos, J. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-46712-9 · Cited by 28
Kwiatkowski, D., Czarny, P. L., Toma, M. M., Imiela, A., Sowinska, K., Gałecki, P., Bachurska, A., Bielecka-Kowalska, A., Szemraj, J., Maes, M. H. J., et al. (2016) · Neuropsychobiology · doi:10.1159/000444643 · Cited by 26
Use of nanoparticles as a potential antimicrobial for food packaging
Nakazato, G., Kobayashi, R. K. T., Seabra, A. B., & Durán, N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804303-5.00012-2 · Cited by 32
Miesner, A. K., & Payne, M. (2018) · Fisheries Oceanography · doi:10.1111/fog.12382 · Cited by 28
Interventions to prevent respiratory diseases - Nutrition and the developing world
Karim, T., Muhit, M., & Khandaker, G. (2016) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2016.09.003 · Cited by 31
Social Science Perspectives on Religion and Climate Change
Berry, E. (2016) · Religious Studies Review · doi:10.1111/rsr.12370 · Cited by 17
Zhang, T., Luu, M. D. A., Dolga, A. M., Eisel, U. L. M., & Schmidt, M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1207280 · Cited by 21
“In AD patients and mouse models, elevated senescent markers, p16, p21, p53 and senescence associated β-Galactosidase (SA-β-Gal) were observed (Arendt et al., 1996; Arendt et al., 1998; McShea et al., 1997; Lüth et al., 2000; Engidawork et al., 2001; Hochstrasser et al., 2011; Esteras et al., 2012; Esteras et al., 2013…”
BackgroundMotor phenotypes and molecular networks associated with germline deficiency of Ciz1
Xiao, J., Vemula, S. R., Xue, Y., Khan, M. M., Kuruvilla, K. P., Marquez-Lona, E. M., Cobb, M. R., & LeDoux, M. S. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.05.006 · Cited by 19
“However, we cannot exclude the possibility that CIZ1 contributes to maturation of one or more cognitive domains or that defective or deficient CIZ1 could cause cognitive decline in older mice (Yates et al., 2015) or plays a role in human Alzheimer's disease (Shen et al.”
BackgroundKarki, R., Madan, S., Gadiya, Y., Domingo‐Fernándéz, D., Kodamullil, A. T., & Hofmann‐Apitius, M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200752 · Cited by 17
“In addition, SOD2 induced oxidative stress [47], TNFRSF1A associated via death domain (TRADD) activated Tnf signaling, and cyclin dependent kinase inhibitor 1A (CDKN1A) activated mitogen-activated protein kinase 9 (MAPK9) [48], mitogen-activated protein kinase kinase kinase 5 (MAP3K5), and Fas cell surface death recep…”
BackgroundShukla, M., & Vincent, B. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230314142505 · Cited by 18
Israel, L. L., Braubach, O., Shatalova, E. S., Chepurna, O. M., Sharma, S., Klymyshyn, D., Galstyan, A., Chiechi, A., Cox, A., Herman, D. A., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106307 · Cited by 14
Cell cycle deregulation in neurodegenerative diseases
Zhang, X., Song, S., & Peng, W. (2021) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924705 · Cited by 15
“This was confirmed in a recent study by Nagy Z [42].”
ResultWidyaningsih, V., Khotijah, & Balgis (2017) · Global Health Action · doi:10.1080/16549716.2017.1339534 · Cited by 19
Broken strands, broken minds: Exploring the nexus of DNA damage and neurodegeneration
Stavgiannoudaki, I., Goulielmaki, E., & Garinis, G. A. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103699 · Cited by 8
Crooke‐Rosado, J., Díaz-Méndez, S. C., Claudio-Roman, Y. E., Rivera, N. M., & Sosa, M. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249801 · Cited by 2
Prince, G. M. S. H., & Dhar, T. G. M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/240820 · Cited by 2
“( Yates et al., 2015) In silico methods with great accuracy was also followed to screen disease associated nsSNPs in many studies using computational tool such as-PolyPhen 2.0, SIFT, PANTHER, I-mutant 3.0, PhD-SNP, SNP&GO, Pmut, and Mutpred etc. (Ali et al., 2017; Kamaraj and Purohit, 2013; Mathe…”
MethodInfluentialBrenner, S. R. (2019) · OBM Geriatrics · doi:10.21926/obm.geriatr.1901035
The molecular effect of a polymorphic microRNA binding site of Wolfram syndrome 1 gene in dogs
Koller, D., Kubinyi, E., Elek, Z., Németh, H., Miklósi, Á., Sasvári‐Székely, M., & Rónai, Z. (2020) · BMC Genetics · doi:10.1186/s12863-020-00879-7
Metadata
- Authors
- Yates, S. C., Zafar, A., Rabai, E. M., Foxall, J. B., Nagy, S., Morrison, K. E., Clarke, C., Esiri, M. M., Christie, S., Smith, A. D., & Nagy, Z.
- Affiliations
- University of Birmingham (GB)
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- Corresponding author
- Nagy, Zsuzsanna
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-01-27
- Volume
- 10
- Issue
- 1
- Pages
- e0114050
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4308198
- OpenAlex
- W2091307037
- Cited by
- 31
- References
- 78
- Citations by year
- 2024: 2 · 2023: 4 · 2021: 4 · 2020: 5 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 5
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (acceptedVersion, cc-by)
- ePrints Soton (University of Southampton) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Funders
- Sir Jules Thorn Charitable Trust
- University of Birmingham
- Medical Research Council (MR/L022656/1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- p21, Alzheimer's disease, Parkinson's disease dementia, genetic polymorphism, cancer-associated variants, cell cycle inhibition, anti-apoptotic effects, neurofibrillary tangles, age of onset, neurodegeneration
- MeSH terms
- Alzheimer Disease, Cell Cycle, Gene Frequency, Humans, Temporal Lobe, tau Proteins, Apoptosis, Age of Onset, Disease-Free Survival, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, White People, Cyclin-Dependent Kinase Inhibitor p21, Kaplan-Meier Estimate, Genetic Association Studies, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.